Results 181 to 190 of about 26,125 (257)

Circulating M‐MDSC Expansion During Therapy Associates With Treatment Response in Multiple Myeloma: A Longitudinal Observational Study

Clinical and Translational Science, Volume 19, Issue 7, July 2026.
ABSTRACT Dynamic changes in myeloid‐derived suppressor cells (MDSCs) during multiple myeloma (MM) treatment remain poorly understood. In this longitudinal observational study, circulating monocytic (M‐MDSCs) and polymorphonuclear MDSCs (PMN‐MDSCs) were measured by flow cytometry in 99 newly diagnosed MM patients at diagnosis, post‐induction, and Day ...
Qi Yan, Bin Chu, Mengru Liu, Na Ji, Shan Gao, Minqiu Lu, Lei Shi, Lijuan Fang, Qiuqing Xiang, Yuan Chen, Mengzhen Wang, Li Bao   +11 more
wiley   +1 more source

Erratum for Li et al., "Bispecific antibodies targeting MPXV A29 and B6 demonstrate efficacy against MPXV infection". [PDF]

J Virol
Li M, Chen J, Wang F, Kuang J, Peng Y, Asghar S, Zhao W, Yang Y, Shen C.   +8 more
europepmc   +1 more source

Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives

European Journal of Haematology, Volume 117, Issue 1, Page 42-54, July 2026.
ABSTRACT Relapsed and refractory multiple myeloma (RRMM) remains associated with poor outcomes, particularly in patients exposed or refractory to proteasome inhibitors, immunomodulatory agents, and anti‐CD38 monoclonal antibodies. Targeting B‐cell maturation antigen (BCMA) has emerged as an effective therapeutic strategy, prompting the development of ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Antibody-based regimens targeting PD-1/PD-L1 and VEGF/VEGFR in advanced or metastatic NSCLC: a meta-analysis of RCTs. [PDF]

Front Immunol
Mao W, Tang Z, Chen Y, Chen Y, Zhang S, Feng X, Zhang S.   +6 more
europepmc   +1 more source

Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs

European Journal of Haematology, Volume 117, Issue 1, Page 24-41, July 2026.
ABSTRACT Acute lymphoblastic leukaemia (ALL) in older adults represents a growing clinical challenge, driven by an ageing population, adverse disease biology, and reduced tolerance to intensive chemotherapy. Although pediatric‐inspired regimens have improved outcomes in younger adults with Philadelphia chromosome (Ph)‐negative ALL, survival in older ...
Antonella Bruzzese, Ernesto Vigna, Enrica Antonia Martino, Santino Caserta, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Marco Fiorillo, Nicola Amodio, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Beyond the chimeric antigen receptor T cells and bispecific antibody duopoly: ex vivo armed T cells for solid tumors. [PDF]

Front Immunol
Park JA, Cheung NV.
europepmc   +1 more source

Incidence and Survival of Hemophagocytic Lymphohistiocytosis Over Two Decades: A Population‐Based Study

European Journal of Haematology, Volume 117, Issue 1, Page 210-218, July 2026.
ABSTRACT Adult hemophagocytic lymphohistiocytosis (HLH) is a rare, life‐threatening syndrome triggered by various conditions. A nationwide study of the incidence and outcomes of HLH in Denmark over 23 years (2000–2023) was performed. Adults (≥ 18 years) with HLH and triggering diseases were identified in the Danish National Patient Registry and/or the ...
Mads Okkels Birk Lorenzen, Martin Jensen, Rasmus Rask Kragh Jørgensen, Paw Jensen, Henrik Frederiksen, Dennis L. Hansen, Daniel El Fassi, Morten Nørgaard Andersen, Tarec Christoffer El‐Galaly   +8 more
wiley   +1 more source

Targeting the CD47/SIRPα interaction in cancer: opportunities in non-Hodgkin lymphoma. [PDF]

Expert Opin Investig Drugs
Pagès-Geli C, Weiskopf K.
europepmc   +1 more source

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience

European Journal of Haematology, Volume 117, Issue 1, Page 144-153, July 2026.
ABSTRACT Patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who progress to the third‐line setting face a lack of standardized treatment, despite the presence of multiple available therapies. In this context, antibody–drug conjugates represent a relatively new class of anticancer agents; among them, loncastuximab tesirine is ...
Francesca Bonello, Andrea Aroldi, Alessia Castellino, Lara Mannelli, Elia Boccellato, Serena Rosati, Luisa Verga, Umberto Vitolo   +7 more
wiley   +1 more source

Late-onset progressive multifocal leukoencephalopathy after teclistamab in multiple myeloma: extending the timeline of infectious risk. [PDF]

Haematologica
Chizzoniti D, Ciambelli F, Latargia ML, Canziani L, Godi C, Pavesi F, Zambrotta GMP, Lotesoriere I, Appio L, Bertolli V, Santamaria C, Ballardini F, Cecchetti C, Todisco E.   +13 more
europepmc   +1 more source